REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO (RGNX) has announced its participation in multiple upcoming investor conferences throughout May and June 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
REGENXBIO (RGNX) has announced its participation in multiple upcoming investor conferences throughout May and June 2025. The company will be present at five major healthcare and biotech events:
- BofA Securities Health Care Conference in Las Vegas (May 13)
- RBC Global Healthcare Conference in New York (May 20)
- H.C. Wainwright BioConnect in New York (May 20)
- Stifel Virtual Ophthalmology Forum (May 27)
- UBS Spring Biotech Conference in New York (June 24)
Select presentations and fireside chats will be available via webcast on REGENXBIO's website, with recordings accessible for approximately 30 days after each event.
Details
News Market Reaction – RGNX
The recorded move for RGNX in the trading session of this news was -18.85%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BofA Securities Health Care Conference 2025
Presentation: Tuesday, May 13, 2025 at 5:00 p.m. PT
Location:
RBC Global Healthcare Conference
Fireside Chat: Tuesday, May 20, 2025 at 11:30 a.m. ET
Location:
H.C. Wainwright BioConnect
Fireside Chat: Tuesday, May 20, 2025 at 4:00 p.m. ET
Location:
Stifel Virtual Ophthalmology Forum
Fireside Chat: Tuesday, May 27, 2025 at 9:30 a.m. ET
Location: Virtual
UBS Spring Biotech Conference
1x1 Investor Meetings: Tuesday, June 24, 2025
Location:
Live webcasts of select presentations and fireside chats can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.
ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-302446818.html
SOURCE REGENXBIO Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.